US FDA grants breakthrough therapy designation to Innate Pharma’s lacutamab for relapsed or refractory Sézary syndrome: Marseille, France Tuesday, February 18, 2025, 12:00 Hrs ...

Innate Pharma has secured US Food and Drug Administration (FDA) breakthrough therapy designation for lacutamab to treat ...

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to ...

Acitretin (Soriatane ®) and bexarotene are the two orally available retinoids used most commonly for treating MF. These drugs are derivatives of vitamin A and are in the same class of agents as ...

Other immunomodulatory effects occur as well (Foss, 2006). It is an outpatient procedure that involves a 2-day treatment cycle repeated every 2 to 4 weeks for months to years, depending on ...

Researchers sought to determine whether the CAR-T therapy volamcabtagene durzigedleucel (CTX130) would be effective in patients with T-cell lymphoma.

These innovations are expanding treatment options, improving patient quality of life, and fueling market growth in the mycosis fungoides landscape. Developments in Early Detection and Diagnostic ...

Diffuse Large B-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive ...

Contribute to anilberman/anil09fab development by creating an account on GitHub.

including the most common subtypes mycosis fungoides and Sézary syndrome, were given DD-cxdl for five consecutive days every 21 days. Roughly 36% of patients responded to the treatment ...

Skip to content Navigation Menu Toggle navigation ...